This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Myelodysplastic syndromes (MDS) are a group of diseases characterized by disruption of blood cell production. A typical case presents as an elderly patient with peripheral blood cytopenia. Diagnostic criteria are based on blood cell counts, as well as assessment of peripheral blood cells and bone marrow for morphologic abnormalities in precursor or mature cells or erythroid, neutrophil, and platelet lineages. Incidence in the United States is thought to be from 1 per 100,000 cases per year to approximately 14,000 new cases per year. Others place the incidence at almost twice that of AML - 24,000 new cases per year. Lovastatin will be provided to the patient as the study drug. It will be administered orally by the patient on a daily basis. Lovastatin will be started on the first day of therapy with Trisenox and continued daily for 16 weeks. Trisenox therapy will be administered per routine clinic practice. For any subjects determined at completion of the 16-week trial to have disease that is stable or responding, Trisenox therapy will be continued and the study drug lovastatin will be stopped.
Showing the most recent 10 out of 381 publications
